In all of these cases, myostatin levels at the 12-month follow-up remained at the detection threshold of the method, including in a SMA type 1 patient for whom treatment with nusinersen was initiated on the same day as baseline sample collection. Here, MSTN is linked to spinal muscular atrophy, type 1.